UPDATE: BMO Capital Markets Raises PT on Ambit Biosciences Following 2Q13 Operating Results

Loading...
Loading...

In a report published Wednesday, BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on Ambit Biosciences AMBI, and raised the price target from $10.00 to $23.00.

In the report, BMO Capital Markets noted, “Ambit Biosciences (AMBI) reported 2Q13 operating results today and provided an update to key initiatives. AMBI ended 2Q13 with $85.3M, sufficient to fund operations though YE15 and the completion of the first quizartinib phase 3 trial. In 2Q13, AMBI held a “Type C” meeting with FDA to discuss in part, requirements for a successful end-of-phase 2 meeting. AMBI characterized the interaction with FDA as highly encouraging, noting that FDA requested documentation supporting the validity of a complete response with incomplete hematologic recovery (CRi) as a surrogate for clinical benefit. AMBI is analyzing internal and external data to support the use of CRi and will present these data along with the complete phase 2b data (FDA saw partial data in 2Q13) and phase 3 study design to FDA in November. AMBI remains on track to initiate a phase 3 trial of quizartinib in relapsed refractory AML in early 2014 with a second phase 3 study in newly diagnosed patients being designed with input from ongoing clinical trials.”

Ambit Biosciences closed on Tuesday at $13.50.

Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsBMO Capital MarketsJim Birchenough
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...